Finch Therapeutics Announces $90 Million Financing to Advance Pipeline of Investigational Oral Microbiome Drugs

Proceeds to support the advancement of lead candidate through the final stages of clinical development for recurrent C. difficile infection, and the advancement into the clinic of programs for autism spectrum disorder and chronic hepatitis B Somerville, MA, September 17, 2020 – Finch Therapeutics Group, Inc. (“Finch”), a clinical-stage microbiome drug development company, announced today[…]


36Kr WISE 2020 Enterprise Service Gold List Released, Rancher Selected as the Only Container Company

On June 24, 2020, Rancher Labs (hereinafter referred to as Rancher), the creator of the most widely used Kubernetes management platform in the industry, announced that Rancher was selected as one of the best cloud solutions for WISE 2020 Enterprise Service Gold List by 36Kr, a well-known venture capital media. Rancher is the only container[…]


Finch Therapeutics Announces Positive Topline Results from Randomized Controlled Trial of CP101, an Oral Microbiome Drug, for the Prevention of Recurrent C. difficile Infection

CP101 met the primary efficacy endpoint with statistically significant improvement in the prevention of recurrent C. difficile infection over standard of care alone in a 206-patient trial CP101 was well-tolerated with no treatment-related serious adverse events CP101 is the first oral microbiome drug to meet its primary endpoint in a pivotal trial Finch announces the[…]

CNBC Named Heal #13 2020 the Most Disruptive Companies out of a List of 50

These are the 2020 CNBC Disruptor 50 companies In the eighth annual Disruptor 50 list, CNBC identifies private companies whose breakthroughs are influencing business and market competition at an accelerated pace. They are poised to emerge from the coronavirus pandemic with tech platforms that have the power to dominate. The start-ups making the 2020 Disruptor list[…]


MegaPro Biomedical was awarded the Start-up Award in the 13th National Innovation Award

May 27, 2019 The outstanding core technology of niche nanomedicine, iron oxide nanoparticles developed by “MegaPro Biomedical”, a biotechnology start-up by ITRI, as well as the future nano-micelle drug carrier received the Start-up Award in the 13th National Innovation Award. After its spin-off from ITRI in 2015, the team in MegaPro Biomedical has been actively[…]


MegaPro Biomedical was invited to “The Third China BioMed Innovation and Investment Conference” hosted by PhIRDA

September 14, 2018 Dr. Jassy Wang will represent MegaPro Biomedical in The Third China BioMed Innovation and Investment Conference hosted by PhIRDA in Suzhou. In addition to interacting with the key pharmaceutical, new drug, and medical equipment companies as well as investment organizations in China, she will conduct a special roadshow between 4.40pm and 5[…]


Apexigen and Yale Cancer Center Announce Clinical Collaboration to Evaluate APX005M, Cabiralizumab, and Opdivo (Nivolumab) in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy

San Carlos, CA, and New Haven, CT – June 14, 2018 Apexigen and Yale Cancer Center today announced a clinical trial collaboration to evaluate Apexigen’s APX005M in combination with cabiralizumab and Opdivo in patients with advanced solid tumors. The Phase 1/2 clinical trial will evaluate the safety, tolerability, and preliminary activity of APX005M in combination with cabiralizumab[…]


Quanergy Wins Silicon Valley Chamber of Commerce Annual Murphy Award

March 19, 2018 Quanergy Systems, Inc., the leading provider of LiDAR sensors and smart sensing solutions, today announced its selection as the recipient of the Silicon Valley Chamber of Commerce’s 2018 Murphy award for Outstanding Innovation in LiDAR Sensing Technology. Issued annually by the Silicon Valley Chamber of Commerce, the award recognizes outstanding accomplishments in[…]